Retroperitoneal fibrosis and constrictive pericarditis-IgG4 related diseases: A case report

Retroperitoneal fibrosis and constrictive pericarditis-IgG4 related diseases: A case report

Retroperitoneal fibrosis (RPF) is a rare disease characterized by infiltration of inflammatory cells and deposition of thickened fibrous tissues. The present study presents the case of a 53-year-old patient treated for generalized weakness and fatigue for 1 year prior to hospitalization. A cardiac u...

Full description

Saved in:
Bibliographic Details
Published in:Experimental and therapeutic medicine Vol. 13; no. 6; pp. 3603 - 3606
Main Authors: Terzic, Brankica, Spasic, Marijan, Djuric, Predrag, Vasiljevic, Vladimir, Radjen, Slavica, Mijuskovic, Mirjana
Format: Journal Article
Language:English
Published: Greece Spandidos Publications UK Ltd 01-06-2017
D.A. Spandidos
Subjects:
Abdomen
Anemia
Autoimmune diseases
Back pain
Blood
Case reports
Histopathology
Immunoglobulins
Kidneys
Laboratories
Males
Medical imaging
Patients
Pericarditis
Proteins
Substance abuse treatment
Tomography
Serbia
Canada
constrictive pericarditis
immunoglobulin G4 related disease
retroperitoneal fibrosis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Retroperitoneal fibrosis (RPF) is a rare disease characterized by infiltration of inflammatory cells and deposition of thickened fibrous tissues. The present study presents the case of a 53-year-old patient treated for generalized weakness and fatigue for 1 year prior to hospitalization. A cardiac ultrasound revealed pericardial effusion that required pericardiocentesis, during which 1,400 ml serous fluid with the characteristics of an exudate was aspirated. A pericardiectomy was performed due to persistent effusion and histological examination indicated pericardial fibrosis. A thoracic-abdominal computed tomography scan revealed the presence of retroperitoneal fibrosis. The patient was treated with corticosteroids and azathioprine. Follow-up examinations showed a significant reduction in the amount of abdominal fibrous tissue and no increase in pericardial effusion 1 year following the end of treatment. The patient continues to have regular follow-up control examinations with a cardiologist and nephrologist.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1792-0981
1792-1015
DOI:10.3892/etm.2017.4425